Drugs Made In America Acquisition II Corp. (DMII)

Profile

Drugs Made In America Acquisition II Corp. is a special purpose acquisition company (SPAC) established in 2024 with the primary objective of effecting business combinations through mergers, share exchanges, asset acquisitions, or similar transactions. The company targets the pharmaceutical industry, aiming to identify and acquire businesses that contribute to reducing U.S. dependence on foreign pharmaceutical manufacturing. By focusing on domestic production and advanced manufacturing technologies for critical drugs, it seeks to help strengthen the American medical supply chain. Incorporated as an exempted company in the Cayman Islands and headquartered in Fort Lauderdale, Florida, the company completed its initial public offering in 2025, raising $500 million. Its structure allows holders of its units to trade ordinary shares and rights separately, enhancing liquidity. This blank check company plays a strategic role as a financial vehicle facilitating investments that support onshoring critical pharmaceutical manufacturing capabilities within the United States.